Merck considering takeover of Cubist Pharmaceuticals

American drug giant Merck is reportedly eying up a possible acquisition of the biopharmaceuticals company Cubist Pharmaceuticals.

The deal, according to the New York Times, could be announced as early as next week. Merck could pay around $100 a share in a move which would value the US antibiotics maker in the range of $7.5 billion.
Cubist, which makes drugs to treat dangerous bacteria and superbugs in the developing world, has seen its share value nearly double over the last two years.
Should the deal go through it would mark the latest in a long line of multibillion-dollar pharmaceutical mergers and acquisitions.
Merck, one of America’s largest makers of vaccines, prescription products and oncology treatments, has a market value in excess of $174 billion.

Related reading:

• Star Wars: The Force Awakens new character revealed: spoiler alert
• Top 5 films about boxes
• Willy Wonka and edible food packaging?
• Braille printing for plastic pharmaceutical packaging
• Plastic banknotes: the colour of money

Author

Phill Allen

Managing Director

Phill is an innovative thinker particularly in fluid management. His expertise lies in ensuring the seamless flow of pharmaceutical liquid logistics, whether it's optimising current processes or pioneering new approaches.

Follow me